Literature DB >> 1246374

Treatment of adenocarcinoma of the endometrium at Memorial-James Ewing Hospitals, 1949-1965.

H D Homesley, R C Boronow, J L Lewis.   

Abstract

This retrospective study of patients receiving initial therapy for endometrial adenocarcinoma at Memorial-James Ewing Hospitals from 1949-1965 confirmed that the most important factor related to survival was extent of disease at presentation. Those patients with spread beyond the corpus had a much poorer prognosis regardless of method of therapy. Within Stage I, histologic grade and depth of myometrial penetration were of much greater prognostic significance than uterine size. Advanced age was associated with a higher incidence of poorly differentiated tumors. Apparently for Stage I, simple hysterectomy alone was not as effective as simple hysterectomy combined with preoperative radium or radical hysterectomy with or without node dissection. There was a 6% incidence of positive nodes when node dissection was performed in Stage I patients who had no spread of disease to the cervix confirmed at operation. Pure vaginal recurrence rate was low for all methods of therapy in Stage I. Eradication of recurrences by any means was relatively ineffective.

Entities:  

Mesh:

Year:  1976        PMID: 1246374

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  3 in total

1.  Diagnosis and management of early carcinoma of the endometrium.

Authors:  L A Walton
Journal:  J Natl Med Assoc       Date:  1978-05       Impact factor: 1.798

2.  The epidemic of endometrial cancer: a commentary.

Authors:  H Jick; A M Walker; K J Rothman
Journal:  Am J Public Health       Date:  1980-03       Impact factor: 9.308

3.  The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered?

Authors:  Nadeem R Abu-Rustum; Qin Zhou; Alexia Iasonos; Kaled M Alektiar; Mario M Leitao; Dennis S Chi; Yukio Sonoda; Robert Soslow; Martee Hensley; Richard R Barakat
Journal:  Int J Gynecol Cancer       Date:  2011-04       Impact factor: 3.437

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.